Cellebrite DI Ltd [CLBT] stock prices are up 1.80% to $18.63 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLBT shares have gain 5.79% over the last week, with a monthly amount glided 13.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cellebrite DI Ltd [NASDAQ: CLBT] stock has seen the most recent analyst activity on March 28, 2024, when Needham reiterated its Buy rating and also boosted its price target to $13.50 from $13. Previously, William Blair upgraded its rating to Outperform on March 13, 2024. On February 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on July 19, 2023. William Blair downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to Neutral for this stock on August 12, 2022, and downed its price target to $6. In a note dated February 24, 2022, JP Morgan initiated an Overweight rating and provided a target price of $10.50 on this stock.
The stock price of Cellebrite DI Ltd [CLBT] has been fluctuating between $13.10 and $26.30 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cellebrite DI Ltd [NASDAQ: CLBT] shares were valued at $18.63 at the most recent close of the market. An investor can expect a potential return of 7.35% based on the average CLBT price forecast.
Analyzing the CLBT fundamentals
The Cellebrite DI Ltd [NASDAQ:CLBT] reported sales of 436.73M for trailing twelve months, representing a surge of 18.35%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at -0.33%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.43 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.36 points at the first support level, and at 18.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.80, and for the 2nd resistance point, it is at 18.98.
Ratios To Look Out For
It’s worth pointing out that Cellebrite DI Ltd [NASDAQ:CLBT]’s Current Ratio is 1.93. As well, the Quick Ratio is 1.90, while the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 10.22, the price to book ratio is 10.92.
Transactions by insiders
Recent insider trading involved ALIAZAR KEINAN, Director, that happened on Sep 24 ’25 when 0.51 million shares were purchased. Officer, RONNEN ARMON completed a deal on Sep 23 ’25 to buy 40535.0 shares. Meanwhile, DIRECTOR AND OFFICER THOMAS HOGAN bought 34151.0 shares on Sep 22 ’25.
